No study has measured salivary flow before and after nicotine pouch use against a non-user comparator, so nobody can tell you that pouches cause dry mouth — and almost everything that has been measured points the other way. Acute nicotine increases saliva output. Snus users were measured at a higher secretion rate than non-users. A menthol mouth rinse raised measured flow. Against that, about 40% of pouch users in one published survey reported a dry mouth, and two clinical trials each logged one mild case. Those are different kinds of fact and this page keeps them apart.
I came to this expecting to explain a mechanism and found that the mechanism runs backwards. The literature on nicotine and saliva is not thin, it is just pointing in the direction nobody repeats: nicotine is a sialagogue. One 2011 paper is so confident about it that it proposes a nicotinic agonist as a treatment for dry mouth. Meanwhile the claim that pouches dry your mouth has a traceable citation chain, and when I followed it to the end the original source says something close to the opposite.
That does not mean nobody’s mouth feels dry. Something is producing those survey numbers. But “a lot of users report a dry feeling” and “pouches reduce salivary flow” are two claims, only one of them has been tested, and it failed. For how pouches work in the mouth generally, start at the nicotine pouches pillar; for the other oral-health question people ask most, do nicotine pouches stain your teeth? takes the same approach to a different outcome.
What has actually been measured in pouch users
More than I expected, and less than you need.
A 2026 randomised crossover study in BMC Oral Health, looking at a tobacco-free pouch and dental plaque, did measure flow properly: “Unstimulated saliva was obtained by drooling for 5 min. The stimulated saliva was collected by chewing on a piece of paraffin and continuously spitting saliva into a graded test tube for 5 min. Secretion rates were calculated in mL/min.” Its two arms came in at 0.315 and 0.51 mL/min unstimulated, and 2.28 and 2.32 mL/min stimulated. But those are baseline descriptors of snus users entering a switching study. Flow was not re-measured afterwards, and there is no non-user group. The study was supported by Swedish Match North Europe AB, and its authors state they received funding and study material from the company.
A 2024 Frontiers in Pharmacology crossover from Germany’s federal risk assessment institute and LMU went further in one respect: it asked. Fifteen smokers used pouches at 0, 6, 20 and 30 mg plus a cigarette comparator, and “Salivation was inquired on a scale from 0 = lowest salivation (dry mouth) over 5 = normal salivation to 10 = highest salivation (hypersalivation).” The result: “No increased salivation was observed and a slightly drier mouth was reported, especially in the tobacco cigarette arm”. So in the one study that measured the sensation across four pouch strengths and a cigarette, the driest arm was the cigarette. That study was funded by BfR’s own intramural programme with no commercial relationships declared. The per-dose figures sit in a supplementary table I could not retrieve, so the dose-response is unchecked rather than absent.
A third study, published in October 2026, collected unstimulated, sub-pressure-stimulated and stimulated saliva from 13 pouch users for metabolomics. Whether it reports flow rates in its body I could not establish — the full text sits behind a publisher that refuses automated access.
Beyond that: across fourteen pouch-specific papers I downloaded, the words “Saxon” and “sialometry” appear nowhere, and “salivary flow” appears in only two, in both cases as speculation or as an e-cigarette finding. The accurate statement is narrow and still strong. No study has used salivary flow in pouch users as an outcome, measured against a non-user comparator.
The direction nicotine actually pushes saliva
This is where the page turns.
In rats, intravenous nicotinic agonists “increased whole saliva output accompanied by a pressor response with nicotine”, and the authors conclude the effect runs through acetylcholine and noradrenaline release at autonomic nerve terminals via the α3β4 receptor subtype. Their closing suggestion is the giveaway: “cytisine may be a better therapeutic candidate to serve as a sialogogue for xerostomia patients.” A sialagogue is a drug that makes you salivate.
In humans, nicotine applied directly to the tongue did the same thing. A 1986 Journal of Physiology study reports: “Lingual apex application of nicotine was associated with a sweet taste and a small rise in salivary secretion rate. This response was not significantly reduced by methylscopolamine.” A 1991 study infusing 20 µg/kg of nicotine intravenously found increased salivary amylase activity and protein concentration in all subjects. A 1971 rabbit parotid study found “Nicotine caused a transient increase in secretion as well as flow rate of amylase.”
Chronic exposure does not reverse it. A 1988 study gave rats nicotine in their drinking water and reported that they “did not show a reduction of salivary flow rate”; the gland changes it did find were attributed to “a nicotine-mediated chronic secretory stimulation” — exhaustion from overwork, not shutdown. The same paper found the opposite in people who smoked: “In smokers and drinkers there was a significantly reduced flow rate of parotid and submandibular saliva.” Smoking is not nicotine.
Even the toxicology runs this way. BfR’s health risk assessment of nicotine pouches lists the symptoms of higher nicotine exposure as including diarrhoea, increased salivation and a slowing of the heart rate. Too much nicotine makes you salivate more.
Snus and snuff: measured, and flow goes up
Worth separating before going further: this page is about how much saliva you make, not about the drip. Snus and saliva: what the drip is and how to manage it covers that, and it is a different problem with a different answer.
The closest proxy for pouches is Swedish snus, and it has been measured repeatedly.
A 2015 study of 102 snus users of ten years or more against 101 matched controls found: “The salivary secretion rate was higher in snus users than non-users (2.5 vs 2.2 ml/min, p = 0.005).” A 1985 study of Finnish recruits found “The salivary flow of resting saliva showed a slightly significant increase compared to controls.” A 1991 Swedish study, explaining a finding about tooth wear, noted that “the salivary flow was more than twice as high when chewing snuff compared to chewing with nothing in the mouth, and that the saliva serves as a lubricant that protects the surface from wear.”
A 2026 systematic review of Swedish smokeless tobacco and oral health from the University of Gothenburg states the finding directly: “saliva secretion rates were found to be higher in users of snus than in non-tobacco users”, though it notes a 2012 study did not support this over time. That review’s PMC record carries no funding or competing-interest statement at all, which is worth saying about the most important review in the area. It also reports that salivary pH was significantly higher with snus use, and that “For the plaque pH, nicotine-containing snus increased it as opposed to nicotine-free products, which lowered the pH”.
Across every smokeless-tobacco cohort I could reach, the results were mixed at worst rather than negative: not different in a 2017 Saudi shammah study, slightly higher in a 2024 study of chewers at 1.75 against 1.51 mL/min, and reduced in a 2025 Indian study — but that last one measured flow with Schirmer tear strips rather than by collection, its exposure was gutka and betel quid with areca nut and lime, and at one minute the users were statistically indistinguishable from controls. One 2025 study did find a real drop, and the detail matters: smokeless users without lesions sat at 0.272 mL/min against controls at 0.277, while users who had developed tobacco pouch keratosis after an average of eighteen years sat at 0.159. Flow fell once the mucosa was damaged, not before.
What people report, which is a different thing
A 2025 survey of 831 adults in Riyadh, with 118 who had ever used oral nicotine pouches, asked about symptoms from a checklist. In the discussion: “Abdominal disturbances were the most common symptom, reported by 47.5% of participants, followed by dry mouth (39.8%), throat symptoms (24.6%), oral ulceration (19.5%), frequent coughing (18.6%), taste alteration and (15.3%).” The paper also records that “However, 22.9% of participants reported no discernible symptoms.” It is a self-administered retrospective checklist with no flow measurement and no non-user comparator, and it was funded by Prince Sattam bin Abdulaziz University.
From the clinical side, two trials each logged exactly one case. A 2022 European Journal of Oral Sciences study of 60 snus users switched to a tobacco-free pouch for six weeks reports: “The events assessed by the investigator as related to the investigational products (the tested non‐tobacco‐based nicotine products) were nausea (two events of mild intensity), dry mouth (mild), gingival blisters (moderate), and dizziness (mild). There were no serious adverse events or discontinuations due to adverse events during the study.” The 2026 plaque study logged “one case of mild dry mouth” among five product-related events. Both were funded by Swedish Match.
So the honest summary is: a dry feeling is a commonly reported sensation and a rare recorded adverse event, and in neither case has it been tied to a measured reduction in saliva.
Where the claim comes from, and where it reverses
This is the part worth printing in full, because the chain is short and it breaks at the end.
A 2025 narrative review in Frontiers in Public Health states that “Potential immediate physiological responses to nicotine pouches include an increase in heart rate, blood pressure, feelings of dizziness, nausea, irritation, headaches, difficulty sleeping, dry mouth, soreness, and a burning sensation in the mouth”, and cites reference 40 for it. Reference 40 is a 2025 review in the journal Quality in Sport. That review contains no primary data — its method is “The review is based on 39 articles found in PubMed databases published between 2006–2024.” — and its only mention of dry mouth is this: “Athletes report that nicotine may aid in managing dry mouth, appetite suppression,”.
The cited source says nicotine may help manage dry mouth. Somewhere between the two papers, the direction flipped.
There is a parallel chain for nicotine generally. A 2024 narrative review in Cureus about nicotine patches asserts that “Nicotine, regardless of its delivery method, can cause a reduction in saliva flow, leading to a condition known as xerostomia or dry mouth”. Its citation for that is a study of long-term smoking. A second dry-mouth sentence in the same paper cites a 2011 trial of oral snus and medicinal nicotine — a paper in which “dry mouth”, “xerostomia” and “saliva” all return zero occurrences. These are not weak citations. They are citations to documents that do not contain the claim.
Mechanism by mechanism
Five candidate mechanisms. Three have been tested and failed, one is unsupported, one survives untested.
Nicotine’s autonomic effect. Tested extensively, and it goes the other way, as above.
Cooling and flavour agents. These are genuinely in pouches and quantified: a 2025 Tobacco Control study from Yale found “the presence of WS-3, an odourless menthol-derived synthetic cooling agent in Zyn Chill (234±7 μg/pouch) as the only major flavourant”, with WS-3 also in the peppermint and spearmint variants. But that paper contains no mention of saliva or dryness, and nor does the one clinical sensory experiment on synthetic coolants — a trial of 84 people comparing WS-23 against menthol rated sweetness, smoothness, bitterness, harshness and coolness, and never asked about dryness. Where cooling agents have been tested against saliva, the result is an increase: a 2020 study found “Menthol and nonivamide mouth rinsing increased saliva flow rates” and that “All the mouth rinses increased mean WMS flow rate compared with unstimulated WMS (UWMS) flow rate (1.0 g/min). The highest concentrations of the three TRP channel agonists stimulated the greatest flow rates; 1.70 ml/min with 500 ppm menthol”. Its authors go on to suggest TRPM8 and TRPV1 agonists have potential in treating chronically dry mouth. That work was funded by a BBSRC studentship subsidised by the flavour house Symrise AG, which is worth knowing.
Humectants and water activity. This is the one that survives. The hygroscopic argument exists in the literature only as an explicit hypothesis and only about e-cigarette liquid: a 2024 Harm Reduction Journal review says “An interesting hypothesis assumes that use of ECs can lead to dry mouth (xerostomia) by action of PG and VG (which are hygroscopic) together with an increase in biofilm volume and a reduced salivary flow”. Nobody has tested it for pouches. What is measured is how dry the pouches themselves are. A 2026 Scientific Reports characterisation of seven brands, funded by Altria Client Services and authored by its employees, reports ZYN at 3.52% moisture content and a water activity of 0.56, on! at 4.48% and 0.57, Velo at 6.62% and 0.56, against wet-format products at 26.6% and 37.2% moisture with water activity of 0.87 and 0.92. A dry pouch at a water activity of 0.56, sitting in a mouth at close to 1.0, will pull water in. That is thermodynamics, not a measurement of dryness, and the paper itself never claims an oral drying effect — its only humectant language is hedged to “humectant-like additives might act as plasticizer”. It is a plausible untested mechanism and I am labelling it as one. Dry versus moist nicotine pouches covers what that moisture difference does to the product itself.
Worth adding, because it cuts against the intuition: propylene glycol was one of the rinses that increased flow in the 2020 study, and in a separate 2025 paper it appears as a formulated ingredient of a commercially marketed dry-mouth mouthwash. Hygroscopic does not automatically mean drying.
Mouth breathing. Tested, and it does not do it. A 2018 study of twenty habitual mouth breathers against twenty nose breathers over six months found “No significant differences were observed in the salivary flow rate all over the observational period”, with means between 1.22 and 1.56 mL/min. And no source I could reach links pouch use to mouth breathing in the first place — that connection is absent from the literature, not merely untested.
Caffeine and dehydration. The one authority that addresses it is the National Institute of Dental and Craniofacial Research, which advises avoiding or limiting caffeinated drinks because “Caffeine can dry out the mouth and lead to dehydration.” If you are using pouches alongside a lot of coffee, that is a confound worth separating before blaming the pouch.
A dry feeling and a dry mouth are not the same measurement
NIDCR’s own patient brochure makes the distinction outright: some people feel they have a dry mouth even if their salivary glands are working correctly. The 2020 saliva study puts a number on how common the sensation is, describing “xerostomia, the perception of a dry mouth, that affects between 10 and 30% of the adult and elderly population”.
The clinical thresholds actually used for unstimulated flow are above 0.25 mL/min for normal, 0.1 to 0.25 for low and under 0.1 for very low. Put the pouch-cohort baseline numbers from earlier against that scale and they sit in the normal-to-low band — which is where you would expect a group of long-term snus users to sit, and tells you nothing about causation either way, because there was no comparator.
For contrast, here is what a measured reduction looks like. In 100 smokers against 100 non-tobacco users: “The mean (±SD) salivary flow rate were 0.38 (± 0.13) ml/min in smokers and 0.56 (± 0.16) ml/min in non-smokers. The difference was statistically significant (P=0.00001). Also, 39% of smokers and 12% of non-smokers reported experiencing at least one xerostomia symptom”. And in a 2025 pilot of twenty vapers: “All vapers (100%) had low resting saliva, whereas the control group had no cases of low resting saliva.” Those are unambiguous effects, found with the study design that pouches have never been given.
What the regulators say, which is nothing
FDA’s 48-page decision summary for the ZYN modified-risk order contains zero occurrences of “salivary”, “xerostomia”, “dry mouth” and “dryness”. Its one mention of saliva is mechanical, about nicotine dissolving in it. The same document says in terms that “there are currently no long-term epidemiological studies pertaining specifically to the proposed MRTPs or nicotine pouch use” and that “The applicant did not submit any observational or clinical studies directly evaluating health outcomes associated with use of the proposed MRTPs.”
The UK’s Delivering better oral health toolkit is the cleanest negative of all. Its chapter on smoking and tobacco use runs to a quarter of a megabyte, discusses smokeless tobacco thirty-four times and snus ten times, and contains zero occurrences of xerostomia, dry mouth, saliva, salivary, caries or tooth decay. Its chapter on dental caries discusses xerostomia six times and salivary flow four times — and contains zero occurrences of tobacco, nicotine, smokeless or pouch. Two chapters of one official toolkit, each holding half the question, never joined.
NIDCR is the instructive case, and it corrects something this site had recorded too simply. Its dry mouth page’s causes list names medicines, disease, radiation therapy, chemotherapy and immunotherapy, and nerve damage — no tobacco, no nicotine. But the same page says “Not using tobacco or alcohol. They dry out the mouth.” under helpful tips, and “and avoiding tobacco and alcohol” under treatment. Two statements outside the causes list, on a page whose causes list excludes it. An absence from one section is not an absence from the document.
Two sibling pages, if the vocabulary rather than the physiology is what you are after: what ‘sun-cured’ tobacco means in snus and regional snus styles across Sweden.
Why it is worth caring about either way
Because saliva does real work. NIDCR: “Dry mouth also increases the risk for tooth decay or fungal infections in the mouth because saliva helps keep harmful germs in check.” The UK caries chapter treats xerostomia as a risk indicator, attributing it to medicines and polypharmacy.
For pouches specifically, the caries question is open and the Gothenburg review says so: “Since there are no studies of white snus or tobacco-free snus, it is not possible to evaluate the risk of caries.” The same review did not find a significant correlation between Swedish snus and caries risk, and separately found that snus “is associated with gingivitis and gingival recession but were not indicative of an increased risk of developing periodontitis”.
And the one thing that is well documented about pouches in the mouth is not dryness but irritation, with a dose relationship. In the BfR crossover, all pouch users reported oral mucosa irritation ranging from moderate at 0 to 20 mg to severe at 30 mg — and note the nicotine-free arm produced moderate irritation too, so irritation is not purely a nicotine effect. A separate survey reported mouth lesions in 48% of users, sore mouth in 37% and sore throat in 21%, although I could only reach that paper’s abstract. A dry, rough feeling under the lip after a strong pouch may be irritation rather than a salivary problem, and those have different answers — why nicotine pouches tingle and pouch pH and why it changes the hit are the two pages that cover the sensations people most often confuse with dryness.
If your mouth feels dry
I am not going to pretend there is pouch-specific advice, because there is no pouch-specific evidence. What the dental authority recommends for dry mouth generally is water — NIDCR suggests 8 to 12 cups a day — sugar-free gum or sugar-free hard candy to stimulate flow, limiting caffeine, and not using tobacco or alcohol. The last of those is the authority’s advice and I am reporting it rather than endorsing or softening it.
Two things worth separating for yourself before deciding the pouch is the cause: whether the feeling is dryness or soreness, and whether it tracks strength. The only dose signal in the literature is for irritation, and it appears at 30 mg.
Frequently asked questions
Do nicotine pouches cause dry mouth? Unknown, and the available evidence leans against it. No study has measured salivary flow as an outcome of pouch use against a non-user comparator. Acute nicotine, snus and menthol have all been measured increasing flow.
Why do so many people say it happens, then? About 40% of pouch users in one Riyadh survey reported a dry mouth from a symptom checklist, and two clinical trials each recorded one mild case. Reported sensation is real data; it just is not the same data as measured flow, and nobody has collected both in the same people.
Is it the cooling agents? No source supports that. WS-3 has been quantified in pouches at around 234 µg per pouch, and the chemistry paper that did it never mentions dryness. Where coolants have been tested against saliva, menthol increased flow to 1.70 mL/min.
Could it be that the pouch itself is dry? That is the one mechanism still standing. Dry-format pouches measure around 3.5 to 6.6% moisture with a water activity near 0.56, so water will move towards the pouch. It has never been tested as a cause of oral dryness, and I am not going to present it as established.
Does dry mouth matter? Yes — NIDCR links it to tooth decay and fungal infection because saliva controls oral bacteria. For tobacco-free pouches specifically, the caries risk cannot currently be evaluated at all, because no study exists.
Sources
- Single-use and six-week effects of a non-tobacco nicotine pouch on dental plaque characteristics, BMC Oral Health, 2026 — the only mL/min flow figures from a pouch cohort; supported by Swedish Match North Europe AB.
- Mallock-Ohnesorg et al., Frontiers in Pharmacology, 2024 — the 0/6/20/30 mg crossover, the salivation scale and the mucosa irritation dose relationship; BfR intramural funding.
- Investigating oral nicotine pouch use among adults in Riyadh, Frontiers in Public Health, 2025 — the 39.8% self-reported dry mouth figure.
- Alizadehgharib et al., European Journal of Oral Sciences, 2022 — the single mild dry-mouth adverse event; funded by Swedish Match AB.
- Frontiers in Public Health, 2025 narrative review — the claim and its citation to reference 40; and Chmiel et al., A review of the health impact of nicotine pouches, Quality in Sport, 2025 (PDF) — reference 40 itself, which says nicotine may aid in managing dry mouth.
- Alayadi, The Impact of Nicotine Patches on Gingival and Oral Health, Cureus, 2024, with Rad et al. on long-term smoking and Kotlyar et al. 2011 on snus and medicinal nicotine — the two documents cited for a claim they do not contain.
- Auton Neurosci, 2011 — nicotinic agonists and whole saliva output; Dunér-Engström et al., Journal of Physiology, 1986; Klin Wochenschr, 1988 — chronic oral nicotine and secretory stimulation. These three have no open full text; the first and third are cited from PubMed because no PMC record exists.
- Hellqvist et al., Swedish Dental Journal, 2015 — 2.5 vs 2.2 mL/min in long-term snus users; and the 2026 University of Gothenburg systematic review of Swedish smokeless tobacco and oral health, whose record carries no funding or competing-interest statement.
- Molecular & Cellular Proteomics, 2020 — TRP channel agonists and saliva flow; funded by a BBSRC studentship subsidised by Symrise AG.
- Tobacco Control, 2025 — WS-3 quantified in ZYN pouches, and the WS-23 sensory trial.
- Dissolution and physical characterization of oral nicotine pouch products, Scientific Reports, 2026 — moisture content and water activity; funded by Altria Client Services LLC.
- Harm Reduction Journal, 2024 critical review — the hygroscopic hypothesis, stated as a hypothesis about e-cigarettes.
- BioMed Research International, 2018 — mouth breathers and salivary flow; Cureus, 2025 — smokeless tobacco with and without pouch keratosis; BMC Oral Health, 2025 — resting saliva in vapers.
- NIDCR, Dry Mouth and its patient brochure (PDF).
- UK, Delivering better oral health, chapter 11 and chapter 4.
- FDA, ZYN modified risk tobacco product decision summary (PDF) and BfR, Health risk assessment of nicotine pouches (PDF).
Last verified 10 November 2026. A 2026 pouch salivary metabolomics paper and the full text of one adverse-event survey sit behind publishers that refuse automated access; both are reported as unchecked rather than as negative.
